


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-21 (Cancelled).

22. (Previously presented) A method of treating trypanosomiasis in a mammal, which comprises administering to a mammal in need thereof an effective amount of a medicinal product comprising a plant extract comprising one or more compounds of the formula (I):



wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ represent, independently of one another:

- a hydrogen atom;
- a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl group;
- a halogen atom;
- halo(C₁-C₁₂)alkyl, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated;
- hydroxyl;
- nitro;
- cyano;
- mercapto;
- carboxylic acid;
- amide;
- amine;
- C₁-C₁₂ alkoxy, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated;
- C₁-C₁₂ alkyl ester, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated,
- secondary or tertiary alkylamide, wherein an C₁-C₁₂ alkyl group(s) thereof is linear, branched or cyclic, and saturated or unsaturated;
- secondary or tertiary alkylamide, wherein an C₁-C₁₂ alkyl group(s) thereof is

linear, branched or cyclic, and saturated or unsaturated, C₁-C₁₂ alkylthio, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated; C₂-C₆ heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of sulfur, nitrogen and oxygen; a group -SO₂-NR'R'' or a group -NR'-SO₂-R'', in which R' and R'' represent, independently of one another, a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl group;

n represents 0 or 1;

R represents a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl group; and

X represents an anion, which is either an inorganic or organic anion.

23. (Currently amended) The method of ~~Claim~~ claim 22, wherein the compound of formula (I) is canthin-6-one.

24. (Currently amended) The method of ~~Claim~~ claim 23, wherein the canthin-6-one is present in the form of an extract of a plant selected from the group consisting of *Ailanrhus altissima*, *Brucea antidyserterica*, *Eurycoma harmandiana*, *Peganum nigellastrum*, *Zanthoxylum elephantiasis* and *Zanthoxylum chiloperone*.

25. (Currently amended) The method of ~~Claim~~ claim 24, wherein the canthin-6-one is present in the form of an extract of *Zanthoxylon chiloperone* var. *angustifolium*.

26. (Currently amended) The method of ~~Claim~~ claim 22, for treating trypanosomiasis in a chronic phase or an acute phase.

27. (Currently amended) The method of ~~Claim~~ claim 22, for treating Chagas' disease.

28. (Currently amended) The method of Claim claim 22, for treating trypanosomiasis caused by *Trypanosoma brucei*.

29. (Currently amended) The method of Claim claim 22, for treating trypanosomiasis caused by *Trypanosoma cruzi*.

30. (Currently amended) The method of Claim claim 23, wherein the plant extract comprising canthin-6-one is obtained by a method comprising the first steps of grinding the dried bark of a trunk of *Zanthoxylum chiloperone* var. *angustifolium*, and then treating the ground dried bark with an aqueous alkaline solution.

31. (Currently amended) The method of Claim claim 30, wherein the plant extract comprising canthin-6-one is obtained by a method further comprising a second step comprising extracting the ground bark and aqueous alkaline solution with a chlorinated organic solvent.

32. (Currently amended) The method of Claim claim 22, wherein the medicinal product is administered at a dose of between about 0.01 and 100 mg/kg/d of compound of formula (I).


33. (Currently amended) The method of Claim claim 32, wherein the administered dose is between about 0.1 and 50 mg/kg/d.

34. (Currently amended) The method of Claim claim 33, wherein the administered dose is between about 1 and 20 mg/kg/d.

35. (Currently amended) The method of Claim 22, wherein the medicinal product is administered orally.

36. (Currently amended) The method of Claim 22, wherein the mammal is a human.

37. (Previously presented) A compound of the formula (I):



(I)

wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ represent, independently of one another:

- a hydrogen atom;
- a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl group;
- a halogen atom;
- halo(C₁-C₁₂)alkyl, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated;
- hydroxyl;
- nitro;
- cyano;
- mercapto;
- carboxylic acid;
- amide;
- amine;
- C₁-C₁₂ alkoxy, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated;
- C₁-C₁₂ alkyl ester, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated;
- secondary or tertiary alkylamide, wherein an C₁-C₁₂ alkyl group(s) thereof is linear, branched or cyclic, and saturated or unsaturated;

secondary or tertiary alkylamide, wherein an C₁-C₁₂ alkyl group(s) thereof is linear, branched or cyclic, and saturated or unsaturated; C₁-C₁₂ alkylthio, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated; C₂-C₆ heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of sulfur, nitrogen and oxygen; a group -SO₂-NR'R'' or a group -NR'-SO₂-R'', in which R' and R'' represent, independently of one another, a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl group;

n represents 0 or 1;

R represents a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl group;

X represents an anion which is inorganic or organic anion, at least one of R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ being different from H, or else n=1; and wherein;

when n= 0, R₂ = R₃ = R₄ = R₅ = R₆ = H and R₈ = OCH₃, then R₁ is different from -OH and -OCH₃;

when n= 0, R₁ = R₂ = R₃ = R₅ = R₆ = R₇ = R₈ = H, then R₄ is different from -OCH₃;

when n= 0, R₁ = R₂ = R₃ = R₄ = R₅ = R₇ = R₈ = H, then R₆ is different from -OH and -OCH₃;

when n= 0, R₁ = R₂ = R₃ = R₄ = R₅ = R₈ = H, then (R₆, R₇) is different from (-OCH₃, -OCH₃);

when n= 0, R₂ = R₃ = R₄ = R₅ = R₆ = R₇ = R₈ = H, then R₁ is different from -OCH₃;

when n= 0, R₁ = R₂ = R₃ = R₄ = R₅ = R₆ = R₇ = R₈, then R₇ is different from -OH;

and

R₇ is different from -OCH₃;

when n 0, R₂ = R₃ = R₄ = R₅ = R₆ = R₇ = H and R₂ = -OCH₃, then R₈ is different from -OH; and

when n = 1, X = Cl, R = CH₃, R₁ = R₂ = R₅ = R₆ = R₇ = R₈ = H and R₃ = -OCH₃ then R₄ is different from -OH.

38. (Currently amended) The compound of Claim 36, wherein X is selected from the group consisting of Cl, Br, I, S, PO₃, NO₃, acetate, oxalate, tartrate, succinate, maleate, fumarate, gluconate, citrate, malate, ascorbate and benzoate.

39. (Currently amended) The compound of Claim 34, wherein one or more of the conditions below are satisfied;

- a) R₃ represents an NH₂ group or a C₁-C₁₂ alkylamine group or a C₃-C₁₂ alkylamide group or a C₂-C₆ heterocycle comprising at least one amine group;

- b) R_4 represents a hydroxyl group or a C_1 - C_{12} alkoxy group; or
- c) $R_1=R_2=R_5=R_7=R_8=H$.

40. (Currently amended) The compound of ~~Claim~~ claim 36, wherein one or more of the conditions below are satisfied:

- a) R_3 represents an NH_2 group or a C_1 - C_6 alkylamine group or a C_1 - C_6 alkylamide group or a C_2 - C_6 heterocycle comprising at least one amine function;
- b) R_4 represents a hydroxyl group or a C_1 - C_6 alkoxy group; or
- c) $R_1=R_2=R_5=R_6=R_7=R_8=H$.

41. (Currently amended) The compound of ~~Claim~~ claim 36, wherein one or more of the conditions below are satisfied:

- a) R_3 represents an NH_2 group;
- b) R_4 represents an OCH_3 group; or
- c) $R_1=R_2=R_5=R_6=R_7=R_8=H$.

42. (Currently amended) The compound of ~~Claim~~ claim 36, wherein $R_1=R_2=R_3=R_4=R_5=R_6=R_7=R_8=H$ and $n=1$, and R is a C_1 - C_6 alkyl group.

43. (Currently amended) The compound of ~~Claim~~ claim 36, which is:
4-aminocanthin-6-one.

44. (Currently amended) The compound of ~~Claim~~ claim 36, which is N-methylcanthin-6-one iodide.

45. (Currently amended) A pharmaceutical composition, which comprises one or more compounds of ~~Claim~~ claim 37, and a carrier.

46. (Previously presented) A pharmaceutical composition, which comprises a plant extract obtained from *Ailanthus altissima*, *Brucea antidysenteria*, *Eurycoma harmandiana*, *Peganum nigellastrum*, *Zanthoxylum elephantiasis* and *Zanthoxylan chiloperone*; and a carrier.

47. (Currently amended) The pharmaceutical composition of ~~Claim~~ claim 46, wherein said plant extract comprises canthin-6-one, 4-aminocanthin-6-one or N-methylcanthin-6-one iodide or a mixture thereof.

48. (Previously presented) A method of treating trypanosomiasis in a mammal, which comprises administering to a mammal in need thereof an effective amount of a plant or an extract thereof selected from the group of *Ailanthus altissima*, *Brucea antidysenteria*, *Eurycoma harmandiana*, *Peganum nigellastrum*, *Zanthoxylum elephantiasis* and *Zanthoxylan chiloperone*; and a carrier.

49. (New) The method of claim 22, wherein for said one or more compounds of the formula (I), n is 0, and one of R₃ or R₄ is other than -H.

50. (New) The compound of claim 37, wherein for said one or more compounds of the formula (I), n is 0, and one of R₃ and R₄ is other than -H.

51. (New) The composition of claim 45, wherein for said one or more compounds of the formula (I), n is 0, and one of R₃ and R₄ is other than -H.